24AUG

WHO: 2,000 Congolese workers get Ervebo

3 min read

17:07UTC

About 2,000 frontline workers in DR Congo had received Ervebo, a vaccine licensed against a different Ebola species, by 10 September; the Bundibugyo trial had not begun.

← Back to Guatemala's measles outbreak outgrew Mexico Jump to analysis ↓

ScienceDeveloping

Key takeaway

Ervebo's Bundibugyo trial is set to open in Ituri while new cases move to North Kivu.

About 2,000 frontline workers in DR Congo had received Ervebo by 10 September, the World Health Organization (WHO) said, from the 70,000 doses released in August⁠¹. Ervebo, made by Merck, is licensed against the Zaire species of Ebola, which caused the 2014-2016 West African epidemic. It is not licensed against Bundibugyo ebolavirus, the species driving this outbreak.

The Phase 3 trial of 20,000 doses against Bundibugyo, the large study that tests whether a vaccine protects, had not begun; WHO expected a start in October or November. The trial uses ring vaccination, immunising the contacts of each new case and their contacts in turn, so it needs fresh cases to measure anything.

With no licensed Bundibugyo vaccine, that trial is the more rigorous of two tests in this outbreak of whether any vaccine protects against it. The other, BRAVO, an MSF study that vaccinates about 20,000 frontline workers in Ituri and North Kivu and follows them for nine to 12 months, began in Bunia on 19 September. WHO said in September that it will begin in Ituri, where cases peaked in mid-August and have declined since. More of the new infections now arise around Butembo in North Kivu, so a trial placed where cases are thinning will collect its answer more slowly.

Deep Analysis

In plain English

Ervebo is a vaccine made for a different type of Ebola, called Zaire, which caused the huge West African outbreak a decade ago. Nobody knows yet if it protects against the Bundibugyo type now spreading in DR Congo. WHO has given it to about 2,000 health workers, just in case. It also plans a proper test, a 'ring' trial, in which the contacts of each new patient are vaccinated to see if fewer of them fall ill. That test only works if there are enough new cases. It is planned for Ituri, the province where cases are now falling.

Deep Analysis

Root Causes

Ervebo exists because the Zaire species caused repeated large outbreaks, giving companies and funders a reason to finish a vaccine. Bundibugyo has caused only a handful of outbreaks since its discovery in Uganda in 2007, so no species-matched product reached licensing.

Ring trials depend on incidence. A trial set up after a province's peak, as in Ituri, recruits slowly because each ring needs a fresh confirmed case.

Cold-chain logistics add delay. Ervebo must be stored frozen at very low temperatures, so every new trial site needs ultra-cold storage set up before the first ring can be vaccinated.

What could happen next?

Risk
An Ituri-only trial could end without an efficacy answer if incidence there keeps falling, as Sierra Leone's 2015 trial did.
Medium term · Suggested
Opportunity
Moving trial sites to Butembo would put the rings where new cases now are.
Short term · Suggested
Consequence
With 48,000 frontline doses still unused on 10 September, the bottleneck is delivery and uptake, not supply.
Immediate · Assessed

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Guinea's 'Ebola ça suffit' ring trial began in April 2015 and showed Ervebo's forerunner protected against the Zaire species, though the West African epidemic was already waning. It worked because Guinea still had steady clusters of new cases in the trial's zones.

Counter-parallel: Sierra Leone's STRIVE trial, launched in 2015, vaccinated health workers but could not measure efficacy because cases fell too fast. It ended as a safety study, which is the outcome an Ituri-only trial risks.

The 70,000 doses came through the International Coordinating Group's Ebola stockpile, so DR Congo did not buy them. A trial result showing cross-protection would turn that existing stockpile into a Bundibugyo tool overnight.

A negative result would leave the outbreak dependent on species-matched candidates still in Phase 1, such as Moderna's mRNA-1469, whose path to large-scale supply is measured in years.

Consensus view: WHO's position, reported by Healio on 10 September, is that a trial is needed to learn whether Ervebo protects against Bundibugyo, and that results 'may take months'. Using 50,000 doses on frontline workers in the meantime is a hedge: if cross-protection exists, those most exposed get it first.

Counter-view: A medRxiv protocol paper (2026.07.09.26357654) modelling Bundibugyo vaccination compares ring designs with wider community campaigns, and the trade-off it sets out cuts against waiting. A ring needs new cases near each enrolled contact, and Ituri's incidence has fallen since mid-August.

Key tension: Whether the trial follows the virus to North Kivu, where it can measure protection, or stays in Ituri, where it was planned and where cases are drying up.

Sources:Healio

Mentions:Guinea →Ervebo →World Health Organization →Ituri Province →Bundibugyo ebolavirus →DR Congo →Zaire ebolavirus →International Coordinating Group on Vaccine Provision →Merck & Co. →Sierra Leone →North Kivu →Phase 3 →Butembo →Ebola →Healio →STRIVE trial →

First Reported In

Update #14 · River boat carries Ebola 1,000 km downriver

Healio· 3 Oct 2026

Read original →

Causes and effects

Caused by

70,000 Ervebo doses, 20,000 as a trial

The 70,000 Ervebo doses released on 20 August supplied the frontline vaccinations and the planned trial.

Occurred 19 Aug 2026

Read story →

Ebola shifts south to DR Congo's Butembo

The trial is to start in Ituri while new cases have moved to North Kivu.

Occurred 23 Sept 2026

Read story →

This Event

WHO: 2,000 Congolese workers get Ervebo

The Phase 3 ring trial is the most rigorous planned test of whether Ervebo protects anyone against Bundibugyo, and it needs fresh cases where it starts. A separate MSF study of frontline workers began on 19 September.

Different Perspectives

Pan American Health Organization

PAHO warned on 20 October that El Niño is set to intensify as the dengue season begins, and issued a regional screwworm alert on 16 October. It wants veterinary and human health workers reporting into one surveillance system.

UK Health Security Agency

UKHSA links three Salmonella Enteritidis clusters to imported eggs and has two large importers under investigation without naming either. Its sequencing led the Food Standards Agency to recall eggs from Kyiv producer Yasensvit.

ECDC

ECDC says Europe's West Nile season affected a broader area than any before and calls Germany's first local Sindbis virus case not unexpected, since the virus was already found in German mosquitoes and birds. It cautions that missing clade data limit how far Europe's clade I mpox rise can be read.

Ghana Ministry of Health

Health Minister Kwabena Mintah Akandoh declared a yellow fever outbreak in the Upper West Region after a Dakar laboratory confirmed three cases, all of whom died. Ghana plans an emergency vaccination campaign in three districts this month.

Government of Côte d'Ivoire

Spokesperson Amadou Coulibaly reported 23 yellow fever cases and 11 deaths in Bounkani on 14 October and said the country holds more than 400,000 vaccine doses. He did not say how many cases were laboratory-confirmed, which leaves the outbreak's true size unclear.

World Health Organization

WHO says no cause has been found for the Irkutsk technician's death and a laboratory-associated exposure cannot be fully excluded. Tedros Adhanom Ghebreyesus urged states to finish the pathogen-sharing annex that holds the Pandemic Agreement back from signature.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.